Matthew Rabinowitz, serving as Executive Chairman of Natera, Inc. (NASDAQ:NTRA), has completed a transaction resulting in the disposition of common stock valued at $280,000. According to filings submitted to the Securities and Exchange Commission, the sale occurred on July 6, 2026. The transaction consisted of the sale of 1,000 shares of Natera common stock at a precise price of $280.00 per share. These specific shares were held indirectly by Rabinowitz’s spouse, rather than through direct personal ownership. The execution of this sale was conducted in accordance with a Rule 10b5-1 trading plan, a mechanism designed to facilitate the pre-arranged sale of securities. Rabinowitz originally adopted this specific trading plan on December 5, 2025.
The timing of this transaction places the sale price in close proximity to the stock’s 52-week high of $288.04. This valuation level follows a period of significant price appreciation, characterized by a 70% return over the past year. Following the completion of this transaction, Rabinowitz’s indirect holdings through his spouse now total 4,000 shares. In contrast, his direct ownership position remains substantial, comprising 2,277,843 shares of Natera common stock. Market data from InvestingPro suggests that the stock may currently be trading at levels that appear overvalued relative to certain metrics. The platform provides 13 additional ProTips for NTRA, alongside a comprehensive Pro Research Report accessible for this equity and over 1,400 other US equities.
In parallel with the insider activity, Natera has advanced its clinical and regulatory profile. The company announced the publication of clinical data in JAMA Oncology concerning its Signatera molecular residual disease (MRD) test. This study, which evaluated data from 298 patients, assessed the test’s predictive capabilities regarding chemotherapy benefits for liver cancer patients. Furthermore, Natera has entered into a partnership with Aveta Biomics to conduct a Phase 3 clinical trial in head and neck cancer. This collaboration will utilize the Signatera test to assess treatment response. On the regulatory front, Natera secured approval from Japan’s Pharmaceuticals and Medical Devices Agency for its Signatera test. This approval marks a significant milestone, as it represents the first PMDA-approved MRD test in Japan. The company intends to launch the test commercially for colorectal cancer in Japan by the end of 2026.
Analyst commentary has also reflected on the company's trajectory. BTIG raised its price target for Natera shares to $270, citing the inclusion of the Signatera MRD test in NCCN guidelines for bladder cancer. Similarly, Bernstein SocGen Group resumed coverage on Natera with an outperform rating, highlighting the company’s path to increased volumes and reimbursement in MRD testing. These developments underscore Natera’s ongoing efforts to expand its testing capabilities and market reach. The stock price data indicates a closing value of 274.25, representing a decline of 7.02 or 2.50% at the close. After-hours trading showed a slight decrease to 273.40, a decline of 0.99 or 0.36%. The company's valuation metrics and clinical milestones continue to draw attention from both institutional analysts and market participants monitoring the biotech sector.